Teva Pharmaceutical Industries (TEVA) Non-Current Assets (2009 - 2026)

Teva Pharmaceutical Industries has disclosed Non-Current Assets across 18 years of filings, most recently posting $26.3 billion for Q1 2026.

• Quarterly Non-Current Assets fell 2.07% year-over-year to $26.3 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $107.8 billion (down 4.47% YoY) and the FY2025 annual result came in at $26.8 billion, changed 0.1% from the prior year.
• Non-Current Assets retreated to $26.3 billion in Q1 2026, from $26.8 billion in the prior quarter.
• Over five years, Non-Current Assets peaked at $34.6 billion in Q1 2022 and troughed at $26.3 billion in Q1 2026.
• A 5-year average of $29.9 billion and a median of $30.5 billion in 2024 frame the typical range for Non-Current Assets.
• Annual changes were most pronounced in 2024 — Non-Current Assets fell 13.62% — and 2025, when it advanced 0.1%.
• Tracing TEVA's Non-Current Assets over 5 years: stood at $32.0 billion in 2022, then fell by 3.02% to $31.0 billion in 2023, then declined by 13.62% to $26.8 billion in 2024, then gained by 0.1% to $26.8 billion in 2025, then decreased by 1.76% to $26.3 billion in 2026.
• Business Quant data shows TEVA's Non-Current Assets at $26.3 billion in Q1 2026, $26.8 billion in Q4 2025, and $27.1 billion in Q3 2025.